Literature DB >> 32915473

Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*.

Maria Gil-Moles1, Uttara Basu1, Rolf Büssing1, Henrik Hoffmeister1, Sebastian Türck1, Agnieszka Varchmin1, Ingo Ott1.   

Abstract

Gold complexes have a long tradition in medicine and for many examples antirheumatic, anticancer or anti-infective effects have been confirmed. Herein, we evaluated the lead compound Auranofin and five selected gold organometallics as inhibitors of two relevant drug targets of severe acute respiratory syndrome coronaviruses (SARS-CoV). The gold metallodrugs were effective inhibitors of the interaction of the SARS-CoV-2 spike protein with the angiotensin converting enzyme 2 (ACE2) host receptor and might thus interfere with the viral entry process. The gold metallodrugs were also efficient inhibitors of the papain-like protease (PLpro) of SARS-CoV-1 and SARS-CoV-2, which is a key enzyme in the viral replication. Regarding PLpro from SARS-CoV-2, the here reported inhibitors are among the very first experimentally confirmed examples with activity against this target enzyme. Importantly, the activity of the complexes against both PLpro enzymes correlated with the ability of the inhibitors to remove zinc ions from the labile zinc center of the enzyme. Taken together, the results of this pilot study suggest further evaluation of gold complexes as SARS-CoV antiviral drugs.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  Auranofin; SARS-CoV-2; coronavirus; gold complexes; metallodrugs

Mesh:

Substances:

Year:  2020        PMID: 32915473      PMCID: PMC7756435          DOI: 10.1002/chem.202004112

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  26 in total

1.  In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins.

Authors:  Raymond Wai-Yin Sun; Wing-Yiu Yu; Hongzhe Sun; Chi-Ming Che
Journal:  Chembiochem       Date:  2004-09-06       Impact factor: 3.164

Review 2.  Recent advances in gold-NHC complexes with biological properties.

Authors:  Malka Mora; M Concepción Gimeno; Renso Visbal
Journal:  Chem Soc Rev       Date:  2018-11-26       Impact factor: 54.564

3.  Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type.

Authors:  Riccardo Rubbiani; Suzan Can; Igor Kitanovic; Hamed Alborzinia; Maria Stefanopoulou; Malte Kokoschka; Susann Mönchgesang; William S Sheldrick; Stefan Wölfl; Ingo Ott
Journal:  J Med Chem       Date:  2011-11-17       Impact factor: 7.446

4.  Alkynyl gold(I) phosphane complexes: Evaluation of structure-activity-relationships for the phosphane ligands, effects on key signaling proteins and preliminary in-vivo studies with a nanoformulated complex.

Authors:  Vincent Andermark; Katrin Göke; Malte Kokoschka; Mohamed A Abu El Maaty; Ching Tung Lum; Taotao Zou; Raymond Wai-Yin Sun; Elisabet Aguiló; Luciano Oehninger; Laura Rodríguez; Heike Bunjes; Stefan Wölfl; Chi-Ming Che; Ingo Ott
Journal:  J Inorg Biochem       Date:  2015-12-30       Impact factor: 4.155

5.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.

Authors:  Riccardo Rubbiani; Igor Kitanovic; Hamed Alborzinia; Suzan Can; Ana Kitanovic; Liliane A Onambele; Maria Stefanopoulou; Yvonne Geldmacher; William S Sheldrick; Gerhard Wolber; Aram Prokop; Stefan Wölfl; Ingo Ott
Journal:  J Med Chem       Date:  2010-11-17       Impact factor: 7.446

6.  Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.

Authors:  Arun K Ghosh; Jun Takayama; Yoann Aubin; Kiira Ratia; Rima Chaudhuri; Yahira Baez; Katrina Sleeman; Melissa Coughlin; Daniel B Nichols; Debbie C Mulhearn; Bellur S Prabhakar; Susan C Baker; Michael E Johnson; Andrew D Mesecar
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 7.  Coronaviruses - drug discovery and therapeutic options.

Authors:  Alimuddin Zumla; Jasper F W Chan; Esam I Azhar; David S C Hui; Kwok-Yung Yuen
Journal:  Nat Rev Drug Discov       Date:  2016-02-12       Impact factor: 84.694

Review 8.  Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.

Authors:  Arun K Ghosh; Margherita Brindisi; Dana Shahabi; Mackenzie E Chapman; Andrew D Mesecar
Journal:  ChemMedChem       Date:  2020-05-07       Impact factor: 3.540

9.  A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.

Authors:  Tiziano Marzo; Luigi Messori
Journal:  ACS Med Chem Lett       Date:  2020-05-08       Impact factor: 4.345

10.  Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*.

Authors:  Maria Gil-Moles; Uttara Basu; Rolf Büssing; Henrik Hoffmeister; Sebastian Türck; Agnieszka Varchmin; Ingo Ott
Journal:  Chemistry       Date:  2020-10-19       Impact factor: 5.236

View more
  15 in total

Review 1.  Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs.

Authors:  Nunzio Iraci; Carmelo Corsaro; Salvatore V Giofrè; Giulia Neri; Angela Maria Mezzasalma; Martina Vacalebre; Antonio Speciale; Antonina Saija; Francesco Cimino; Enza Fazio
Journal:  Biomolecules       Date:  2022-07-30

Review 2.  Advances in nanotechnology application in biosafety materials: a crucial response to COVID-19 pandemic.

Authors:  Rasmi V Morajkar; Akhil S Kumar; Rohan K Kunkalekar; Amit A Vernekar
Journal:  Biosaf Health       Date:  2022-06-24

3.  Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.

Authors:  Lennart Brewitz; Jos J A G Kamps; Petra Lukacik; Claire Strain-Damerell; Yilin Zhao; Anthony Tumber; Tika R Malla; Allen M Orville; Martin A Walsh; Christopher J Schofield
Journal:  ChemMedChem       Date:  2022-02-17       Impact factor: 3.540

Review 4.  Metal Complexes as Antiviral Agents for SARS-CoV-2.

Authors:  Johannes Karges; Seth M Cohen
Journal:  Chembiochem       Date:  2021-06-14       Impact factor: 3.461

5.  ReI Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease.

Authors:  Johannes Karges; Mark Kalaj; Milan Gembicky; Seth M Cohen
Journal:  Angew Chem Int Ed Engl       Date:  2021-03-26       Impact factor: 16.823

6.  Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2.

Authors:  Christina Chuong; Christine M DuChane; Emily M Webb; Pallavi Rai; Jeffrey M Marano; Chad M Bernier; Joseph S Merola; James Weger-Lucarelli
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

7.  Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*.

Authors:  Maria Gil-Moles; Uttara Basu; Rolf Büssing; Henrik Hoffmeister; Sebastian Türck; Agnieszka Varchmin; Ingo Ott
Journal:  Chemistry       Date:  2020-10-19       Impact factor: 5.236

Review 8.  Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules.

Authors:  Rossana Galassi; Lorenzo Luciani; Junbiao Wang; Silvia Vincenzetti; Lishan Cui; Augusto Amici; Stefania Pucciarelli; Cristina Marchini
Journal:  Biomolecules       Date:  2022-01-05

9.  Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.

Authors:  William Ndugire; N G Hasitha Raviranga; Jingzhe Lao; Olof Ramström; Mingdi Yan
Journal:  Adv Healthc Mater       Date:  2021-08-05       Impact factor: 11.092

10.  Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.

Authors:  Mohammad Tarek; Andrea Savarino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.